EAN News

Our authors of the month for September conclude that people with Parkinson's Disease and parkinsonism showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic.

A special EAN edition of German-language publication BrainMag was published in August, featuring reports from the EAN 2022 congress and an interview with the Editor-in-Chief of the EAN e-learning platform, eanCampus.

The final EPICLUSTER meeting will take place on 29 September, in Brussels and online, under the heading 'Shaping the future of epilepsy research in Europe.

Three free educational webinars on rare neurological and movement disorders coming up in September, held jointly by the European Reference Network for Rare Neurological Diseases (ERN-RND) and EAN.

Our highlighted selection of Covid-related Literature Reviews from the scientific press for August 2022.

Our selection of miscellaneous Covid-related studies from the scientific press for August 2022.

Our editors' pick of Covid-related cross-sectional case control studies from the scientific press for August 2022.

Our highlighted selection of Covid-related meta-analyses and systemic reviews from the scientific press for August 2022.

Registration is open for the 2nd edition of the Brain Innovation Days, taking place on 11-12 October, 2022, in Brussels, Belgium.

The EBRA Final Conference will take place on 11 October, 2022, in Brussels, Belgium, featuring a talk from EAN President, Prof. Paul Boon on Conclusions on the brain Research Challenges and Priorities in Europe.

A joint session between the International Federation of Clinical Neurophysiology and EAN will be held during the ICCN 2022 in September.

6th Rijeka Forum on Neurodegenerative Diseases “Neurodegeneration updates and the 30 years of Amyloid Cascade Hypothesis” September 25-28, 2022 This event is organised by the Clinic of Neurology UHC Rijeka together with the Croatian Academy of Sciences and Arts and… Continue Reading

The new EAN President-Elect highlights some hopes and objectives for the future of the EAN, including updates on the work of the Covid-19 Task Force and the Coordinating Panel on Diversity, Equity and Inclusion in Neurology.

Our research paper of the month presents the results of the ‘SWIFT direct’ trial, a randomised, open-label, blinded-outcome trial, aiming to investigate whether thrombectomy alone would be non-inferior to thrombectomy plus intravenous alteplase in patients with acute ischaemic stroke due to anterior circulation large vessel occlusion.

The EAN Neuro-covid ReGistrY has now collected over 3,400 cases from more than 40 centres all over the world. Get involved!